Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab

Anti-PD-L1 antibodies benefit many cancer patients, even those with “non-inflamed tumor”. Determining which patients will benefit remains an important clinical goal. In a non-inflamed tumor mouse model, we found that PD-L1 was highly expressed on antigen-presenting cells (APCs) especially on CD103(+...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwai, Toshiki, Sugimoto, Masamichi, Patil, Namrata S., Bower, Daniel, Suzuki, Miho, Kato, Chie, Yorozu, Keigo, Kurasawa, Mitsue, Shames, David S., Kondoh, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260627/
https://www.ncbi.nlm.nih.gov/pubmed/34230534
http://dx.doi.org/10.1038/s41598-021-93113-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260627/
https://www.ncbi.nlm.nih.gov/pubmed/34230534
http://dx.doi.org/10.1038/s41598-021-93113-y

Ejemplares similares